Head-to-Head Comparison of 68 Ga-NODAGA-JR11 and 68 Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study

作者：Zefang Lin, Wenjia Zhu, Jiaying Zhang, Weibing Miao, Shaobo Yao, Li Huo · 发表于：Journal of Nuclear Medicine · 年份：2023 · DOI：10.2967/jnumed.122.264890 · 被引用次数：35 · 研究领域：Neuroendocrine Tumor Research Advances、Neuroblastoma Research and Treatments、Lung Cancer Research Studies

The current study aimed to compare 68 Ga-NODAGA-Cpa-cyclo(d-Cys-amino-Phe-hydroorotic acid-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH 2 (JR11) and 68 Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. Methods: A prospective bicenter study aimed at enrolling 100 patients with histologically proven, metastatic or unresectable, well-differentiated neuroendocrine tumors was conducted. The first 48 patients represented the study cohort. Each patient received 68 Ga-DOTATATE on the first day and 68 Ga-NODAGA-JR11 on the second day. Whole-body PET/CT scans were performed at 40–60 min after injection. Normal-organ uptake, lesion numbers, lesion uptake, and sensitivity were compared. The potential impact on clinical management was also determined. Results: Overall, 68 Ga-NODAGA-JR11 demonstrated lower background uptake in normal organs. Compared with 68 Ga-DOTATATE, 68 Ga-NODAGA-JR11 detected significantly more liver lesions (673 vs. 584, P = 0.002). The target-to-background ratio of liver lesions was significantly higher on 68 Ga-NODAGA-JR11 (6.4 ± 8.7 vs. 3.1 ±2.6, P = 0.000). Comparable uptake was observed for primary tumors, bone lesions, and lymph node metastases. In total, 180 lesions were detected on conventional imaging in 15 patients; 165 and 139 lesions of them were positive on 68 Ga-NODAGA-JR11 and 68 Ga-DOTATATE, leading to a sensitivity of 91.7% and 77.2%, respectively. In 14.5% (7/48) of patients, 68 Ga-NODAG...